Cyclin-dependent kinases as targets for cancer therapy.

Manish A Shah, Gary K Schwartz
{"title":"Cyclin-dependent kinases as targets for cancer therapy.","authors":"Manish A Shah,&nbsp;Gary K Schwartz","doi":"10.1016/s0921-4410(03)21007-3","DOIUrl":null,"url":null,"abstract":"<p><p>Cell cycle perturbations are commonly observed in human malignancies. Exploiting this finding is the rationale for the development of CDK inhibitors as anti-tumor agents. Single-agent evaluation of several CDKIs has demonstrated limited clinical activity. The combination of CDKIs with standard cytotoxic agents is an emerging, alternative approach to anticancer therapy that also exploits the cell cycle perturbations of malignancy. Pre-clinical studies demonstrate the concept of cell cycle mediated drug resistance, and suggest that the combination of standard cytotoxic agents with CDKIs will require thoughtful sequencing and scheduling. With this in mind, there are presently several clinical investigations underway examining the combination of a standard cytotoxic with a novel CDKI, with particular attention to sequence and scheduling. Although phase II evaluation of these combination studies will provide initial evidence of anti-tumor activity, definitive phase III studies will be needed to establish this class of agents in the care of patients with cancer.</p>","PeriodicalId":72508,"journal":{"name":"Cancer chemotherapy and biological response modifiers","volume":"21 ","pages":"145-70"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer chemotherapy and biological response modifiers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0921-4410(03)21007-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

Cell cycle perturbations are commonly observed in human malignancies. Exploiting this finding is the rationale for the development of CDK inhibitors as anti-tumor agents. Single-agent evaluation of several CDKIs has demonstrated limited clinical activity. The combination of CDKIs with standard cytotoxic agents is an emerging, alternative approach to anticancer therapy that also exploits the cell cycle perturbations of malignancy. Pre-clinical studies demonstrate the concept of cell cycle mediated drug resistance, and suggest that the combination of standard cytotoxic agents with CDKIs will require thoughtful sequencing and scheduling. With this in mind, there are presently several clinical investigations underway examining the combination of a standard cytotoxic with a novel CDKI, with particular attention to sequence and scheduling. Although phase II evaluation of these combination studies will provide initial evidence of anti-tumor activity, definitive phase III studies will be needed to establish this class of agents in the care of patients with cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
细胞周期蛋白依赖激酶作为癌症治疗的靶点。
细胞周期紊乱常见于人类恶性肿瘤。利用这一发现是开发CDK抑制剂作为抗肿瘤药物的基本原理。对几种CDKIs的单药评估显示其临床活性有限。CDKIs与标准细胞毒性药物的结合是一种新兴的抗癌治疗替代方法,它也利用了恶性肿瘤的细胞周期扰动。临床前研究证明了细胞周期介导的耐药概念,并表明标准细胞毒性药物与CDKIs的结合需要深思熟虑的测序和计划。考虑到这一点,目前有几项临床研究正在研究标准细胞毒素与新型CDKI的组合,特别注意序列和计划。虽然这些联合研究的II期评估将提供抗肿瘤活性的初步证据,但确定的III期研究将需要建立这类药物在癌症患者护理中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Brain tumors. Sarcomas. Lung cancer. Chapter 17, Achievements in Targeted Therapies - ERS Monographs - Lung Cancer Breast Cancer: Index
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1